Norwood, MA, United States of America

Luis Torres

This inventor holds 2 USPTO granted patents and 7 EPO patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2024-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Luis Torres. Retrieved from https://idiyas.com/inventor/luis-torres-q7taya5w

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 18.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Luis Torres in the Field of Pharmaceutical Chemistry

Introduction

Luis Torres is an accomplished inventor based in Norwood, MA, who has made significant contributions to the field of pharmaceutical chemistry. With a focus on developing innovative compounds, he has been instrumental in advancing treatments for diseases such as Parkinson's Disease. His work has led to the filing of two patents that showcase his expertise and dedication to improving healthcare.

Latest Patents

Luis Torres holds two notable patents. The first patent is for "1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." This invention is directed towards certain substituted 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives, which are potent inhibitors of LRRK2 kinase. These compounds may be useful in the treatment or prevention of diseases where LRRK2 kinase is involved, including Parkinson's Disease. The patent also covers pharmaceutical compositions comprising these compounds and their applications in disease prevention and treatment.

The second patent is for "N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." This invention focuses on substituted N-heteroaryl indazole derivatives, which are also potent inhibitors of LRRK2 kinase. Similar to the first patent, this invention aims to provide therapeutic options for diseases associated with LRRK

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…